Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 2/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181292 | 1.00 | CYP2D6 (0.52) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL506784 | 1.00 | CYP2D6 (0.52) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL25859829 | 0.91 | CYP2D6 (0.50) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL21488522 | 0.91 | CYP2D6 (0.50) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL435571 | 0.90 | CYP2D6 (0.58) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL4641154 | 0.90 | CYP2D6 (0.51) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL25173913 | 0.90 | CYP2D6 (0.49) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL181141 | 0.87 | CYP2D6 (0.54) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL29656200 | 0.86 | CYP2D6 (0.51) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL21036753 | 0.84 | TSHR (0.38) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 412 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171996-A1 | PROCESS FOR ENANTIOSELECTIVE ENZYMATIC REDUCTION OF KETO COMPOUNDS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2021-06-10 | — | — | US | claimed |
| US-20190202814-A1 | PROCESSES FOR PREPARATION OF EMPAGLIFLOZIN | CADILA HEALTHCARE LIMITED (IN) | 2019-07-04 | — | — | US | claimed |
| WO-2017203457-A1 | SOLID STATE FORMS OF EMPAGLIFLOZIN | DR. REDDY'S LABORATORIES LIMITED (IN) | 2017-11-30 | — | — | WO | claimed |
| US-20170247356-A1 | PROCESSES FOR THE PREPARATION OF EMPAGLIFLOZIN | CADILA HEALTHCARE LIMITED | 2017-08-31 | — | — | US | claimed |
| EP-4737453-A1 | NOVEL SELENOPHENE DERIVATIVES | Aigen Sciences Inc. (KR) | 2026-05-06 | — | — | EP | disclosed |
| US-20260103463-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-04-16 | — | — | US | disclosed |
| US-20260055105-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-02-26 | — | — | US | disclosed |
| EP-4638442-A1 | TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS | Uniquest Pty Limited (AU) | 2025-10-29 | — | — | EP | disclosed |
| US-12435066-B2 | Substituted tricyclic compounds | LUPIN LIMITED (IN) | 2025-10-07 | — | — | US | disclosed |
| EP-4615454-A1 | SOS1 INHIBITORS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-09-17 | — | — | EP | disclosed |
| US-12410168-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-20250276966-A1 | Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives | PFIZER (US) | 2025-09-04 | — | — | US | disclosed |
| WO-2007007041-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006125972-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005118531-A1 | AMINOMETHYL-AZACYCLE DERIVATIVES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| EP-1594867-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | Prosidion Limited (GB) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20040181067-A1 | Tri(cyclo) substituted amide compounds | OSI PHARMACEUTICALS, INC. | 2004-09-16 | — | — | US | disclosed |
| WO-2004072031-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | PROSIDION LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202814-A1 | PROCESSES FOR PREPARATION OF EMPAGLIFLOZIN | SLC5A2, SLC5A1, SLC2A4 | CYP2D6 100/4885CYP1A2 253/4885CYP3A4 52/4885 |
| US-12410168-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | CYP2D6 3097/4885CYP1A2 1910/4885CYP3A4 2881/4885 |
| US-20170247356-A1 | PROCESSES FOR THE PREPARATION OF EMPAGLIFLOZIN | SLC5A2, SLC5A1, SLC2A4 | CYP2D6 105/4885CYP1A2 292/4885CYP3A4 60/4885 |
| US-20040181067-A1 | Tri(cyclo) substituted amide compounds | GPR119, IAPP, SLC5A1 | CYP2D6 615/4885CYP1A2 446/4885CYP3A4 422/4885 |
| US-20260103463-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | CYP2D6 813/4885CYP1A2 2001/4885CYP3A4 1988/4885 |
| US-20250276966-A1 | Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives | CCNI, MKI67, CCNA1 | CYP2D6 53/4885CYP1A2 732/4885CYP3A4 601/4885 |
| US-20260055105-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GIPR, GPR119 | CYP2D6 1965/4885CYP1A2 2778/4885CYP3A4 2193/4885 |
| US-12435066-B2 | Substituted tricyclic compounds | SOS1, RSU1, KSR1 | CYP2D6 2174/4885CYP1A2 3207/4885CYP3A4 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.